Close

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

2014 Annual Report

We have a clear and focused strategy to become a leading global biotech delivering innovative medicines to patients with rare diseases and other specialty conditions.

View our 2014 Annual Report (HTML) 

Download our 2014 Annual Report (PDF)

2014 Annual Responsibility Review

Learn about our committment to Responsibility.

Read more

 

New Initiative Aimed
At Improving Diagnosis

Watch our video

Launch our infographic

Read more

 

Shire completes acquisition of NPS Pharma

NPS Pharma is an excellent strategic fit that will enhance Shire’s commitment to patients with life-altering conditions utilizing our global strength in both rare diseases and GI.
 
View Press Release 

 

Full Year 2014 Results

Flemming Ornskov, MD, Chief Executive Officer presents Shire's Full Year results for 2014.

View the Press Release  
Re-play the webcast  
Download the presentation 
Download the Shire IR App AppStore

 

Share price



29 Mar 2015
At least 15 minutes delayed

Our products

Shire has a wide range of products on the market and will ensure that it can make more products available in the future.

 

Our responsibility

We are proud to be on the Global 100 Sustainability Index.

View the press release

Learn More

Global 100 Most Sustainable

We're pleased to announce that we have again been recognized as a constituent of the FTSE4Good Index Series. Read more

FTSE4Good

Responsibility

What Responsibility means to Shire. Read more here.

Our stance on ADHD

Shire Opposes Misuse, Abuse and
Diversion of Prescription ADHD
Medicines. Read more here.